[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527635":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":39,"locations":49,"responsibleParty":65,"collaborators":44,"id":67,"slug":44,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":44,"enrollmentInfo":75,"targetDuration":44,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":52,"whyStopped":44,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Hospital, Angers","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"medical honey","EXPERIMENTAL","the patients randomised to this arm will have honey (Activon® Advancis Medical.)",[13],"Device: medical honey Activon® 25g Tube",{"label":15,"type":16,"description":17,"interventionNames":18},"standard of care","ACTIVE_COMPARATOR","the patients randomised to this arm will have standard of care recommanded by HAS (french organisation)",[19],"Device: standard of care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","medical honey Activon® 25g Tube","no blinding procedures will be set up for the adminisration of the treatement",[9],[9],{"type":22,"name":15,"description":24,"armGroupLabels":28,"otherNames":29},[15],[30],"recommendation of HAS ( french administration)",[32,36],{"name":33,"affiliation":34,"role":35},"Sigismond LASOCKI, MD, PhD","anethesia and critical care department, CHU Angers","STUDY_CHAIR",{"name":37,"affiliation":34,"role":38},"catherine ROD","PRINCIPAL_INVESTIGATOR",[40,46],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Catherine CR ROD, NURSE","CONTACT","0241353635",null,"arcdar-angers@chu-angers.fr",{"name":47,"role":42,"phone":43,"phoneExt":44,"email":48},"Sigismond SL LASOCKI, PUPH","silasocki@chu-angers.fr",[50],{"facility":51,"status":52,"city":53,"state":44,"zip":44,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Angers University Hospital, surgical reanimation","RECRUITING","Angers","France",{"type":56,"coordinates":57},"Point",[58,59],-0.55202,47.47156,{"lat":59,"lon":58},[62],{"name":63,"role":42,"phone":43,"phoneExt":44,"email":64},"Catherine ROD","Catherine.Rod@chu-angers.fr",{"type":66,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100527635",false,"NCT06150326","Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study.","MICAREA","Inclusion Criteria:\n\n* Hospitalization in surgical intensive care unit A -USC PTO CHU ANGERS\n* Informed consent signed by patient or relative (or emergency inclusion procedure)\n* Patient with one or more wounds ≥ 4 cm2, evolving for less than 8 days, including: stage 2, 3, 4 pressure sores, lacerations, ulcers, dermabrasions and scar disunions.\n\nExclusion Criteria:\n\n* Patients with honey intolerance\u002Fallergy to bee stings\n* Patients with wounds lasting more than 8 days\n* Patient with a bleeding wound,\n* Patient with a tunneled wound\n* Patients with chronic dermatoses\n* Patient with an estimated life expectancy \\\u003C 15 days\n* Expected discharge ≤48 hours.\n* No affiliation to a French social security scheme or beneficiary of such a scheme.\n* Pregnant, breast-feeding or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person subject to a legal protection measure","ALL","18 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"NA","Wound management is a real public health issue in France. To date, a wide range of devices exists to treat these wounds, depending on their nature and stage of evolution. Honey has been proposed for the care of wounds and is effective in reducing the surface of wounds and the pain perceived by patients. Inanition, its use is very simple compared to usual care, requiring different types of dressing accross time. In the intensive care unit, patients are prone to suffering or developing numerous types of wound, but the interest of honey has not been investigated yet.\n\nWe propose a prospective, monocentric, randomized, single-blind, controlled clinical trial to assess the efficacy of managing acute cutaneous wounds with honey (Activon®) compared with standard care, in intensive care patients. The primary endpoint is the percentage of wound surface area reduction measured at 15 days from inclusion.",[83,84],"Wound Heal","Critical Illness",[86],"HONEY","2026-03-31",{"date":89,"type":90},"2026-04-06","ACTUAL",{"date":92,"type":90},"2024-06-11",{"date":94,"type":77},"2028-04",{"name":5,"class":6},1]